Skip to main content

Advertisement

Log in

Melanoma in a patient in treatment with eculizumab

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Hillmen P, Young NS, Schubert J et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233–1243

    Article  PubMed  CAS  Google Scholar 

  2. Psaty EL, Scope A, Halpern AC, Marghoob AA (2010) Defining the patient at high risk for melanoma. Int J Dermatol 49(4):362–376

    Article  PubMed  Google Scholar 

  3. Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd DR, Buzaid AC et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206

    Article  PubMed  Google Scholar 

  4. Laroni A, Bedognetti M, Uccelli A, Capello E, Mancardi GL (2011) Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci 32(1):181–182

    Article  PubMed  CAS  Google Scholar 

  5. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and risk of malignancy: analyses from a large US observational study. Arch Rheum 56:2886–2895

    Article  Google Scholar 

  6. Askling J, Bongartz T (2008) Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 20:334–339

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

The authors declare that they have no conflicts of interest to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ausilia Maria Manganoni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manganoni, A.M., Pavoni, L., Facchetti, F. et al. Melanoma in a patient in treatment with eculizumab. Ann Hematol 91, 135–136 (2012). https://doi.org/10.1007/s00277-011-1229-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-011-1229-9

Keywords

Navigation